(PQD5) Avatar-directed Treatment for Ovarian Cancer

Project: Research project

Description

Project Summary
In 2012, an estimated 22,300 American women will develop ovarian carcinoma (OC) and 15,500 will die of this
disease. These statistics highlight the need for improved understanding of the biology of this cancer and
improved approaches to therapy. To address this, we have developed treatment-na¿ve, intraperitoneally-
engrafted, patient-derived xenografts in SCID mice from consecutive patients with ovarian, primary peritoneal,
and fallopian tube cancers for the development of novel therapeutics and understanding of OC biology. To
date, we have been successful in engrafting over 160 individual models from OC patients of all subtypes,
which engraft at a very high rate (~70-75%). These models accurately recapitulate the source patients' tumor
histologically and molecularly. Most importantly, the response of Avatar models to cytotoxic chemotherapy is
concordant with patient outcomes. Specifically, patients with platinum-resistant OC (PR-OC) have Avatars that
do not respond to platinum-based chemotherapy. Conversely, Avatar regress in response to platinum-based
chemotherapy originating from patients with platinum-sensitive OC. We now propose to use Avatar models to
direct therapy in patients with PR-OC. To reach these goals, we propose to: 1) Development of Avatar
models: We will determine the MTD of the four standard salvage agents for patients with PR-OC (topotecan,
paclitaxel, gemcitabine, pegylated liposomal doxorubicin). Patients' individual Avatar models will be expanded
in the presence of platinum-based chemotherapy, to recapitulate the tumors chemotherapy responsiveness in
the patient with PR-OC. To optimize our methodology we will evaluate several interventions aimed at
improving the rate of and time to engraftment. In anticipation of accommodating the generation of Avatar
models for directing chemotherapy in patients from other institutions, we will assess the feasibility of generating
models at a high rate with tumor shipped from the Mayo Clinic-Arizona and Mayo Clinic-Florida to Mayo Clinic-
Rochester. 2) Determination of optimal chemotherapy agent for Avatars. We will determine the sensitivity
of the individual platinum-resistant Avatar models to the four salvage chemotherapy agents and recommend a
'winning' treatment (or treatments) for each patient at the time she develops PR-OC. Array CGH, SNP and
transcriptome profiling will be performed to identify the signature of response to individual agents, which will be
enhanced by comparisons among the individual agents to remove generalized chemotherapy responsiveness
signature components. 3) Clinical trial of Avatar-directed therapy. Using the individual Avatar response data,
treatment will be directed to one of the salvage chemotherapy agents in patients on a phase II clinical trial.
Concordance between the Avatar response and patient outcomes will be used to further enrich the signature of
response to the four chemotherapy agents. Future studies will then aim to validate the signature.
StatusFinished
Effective start/end date5/13/144/30/18

Funding

  • National Institutes of Health: $621,606.00

Fingerprint

Ovarian Neoplasms
Platinum
Drug Therapy
Therapeutics
Carcinoma
Proxy
gemcitabine
Fallopian Tube Neoplasms
Topotecan
Neoplasms
Phase II Clinical Trials
SCID Mice
Paclitaxel
Heterografts
Single Nucleotide Polymorphism
Clinical Trials

ASJC

  • Medicine(all)